Digest Network Come funziona
Network
/
Società
Ab
Non verificato

Abcuro, Inc.

Di cosa scriviamo

BiotecnologiaFarmaceuticaMedicina - VarieOncologiaSalute

8 comunicati stampa

Guarda tutti i comunicati
03/11/2025
Oncologia
Salute
Medicina - Varie
Sanità
Farmaceutica
Biotecnologia
Eventi
Industria
Abcuro to Present Interim Phase 1 Data Evaluating Ulviprubart in Patients with T Cell Large Granular Lymphocytic Leukemia at the 67th American Society of Hematology Annual Meeting
Fonte
Abcuro, Inc.
Emittente
Business Wire
1.00
0
09/06/2025
Mercato del lavoro
Oncologia
Salute
Medicina - Varie
Sanità
Farmaceutica
Biotecnologia
Abcuro Appoints Courtney Cupples as Chief Commercial Officer
Fonte
Abcuro, Inc.
Emittente
Business Wire
1.00
0
11/03/2025
Industria
Eventi
Oncologia
Salute
Medicina - Varie
Sanità
Farmaceutica
Biotecnologia
Abcuro to Present Two Posters at the American Academy of Neurology 2025 Annual Meeting
Fonte
Abcuro, Inc.
Emittente
Business Wire
1.00
0
12/02/2025
Biotecnologia
Farmaceutica
Salute
Oncologia
Abcuro Announces $200 Million Series C Financing to Advance Its First-In-Class Medicine in Development for Inclusion Body Myositis
Fonte
Abcuro, Inc.
Emittente
Business Wire
1.00
0
11/11/2024
Eventi
Oncologia
Salute
Scienza
Medicina - Varie
Biotecnologia
Abcuro Announces Participation in Upcoming Investor Conferences
Fonte
Abcuro, Inc.
Emittente
Business Wire
1.00
0
29/08/2024
Scienza
Medicina - Varie
Biotecnologia
Salute
Farmaceutica
Sanità
Oncologia
Eventi
Web e Social Network
Abcuro Announces Participation in Upcoming Investor Conferences
Fonte
Abcuro, Inc.
Emittente
Business Wire
1.00
0
31/07/2024
Oncologia
Salute
Medicina - Varie
Scienza
Farmaceutica
Biotecnologia
Mercato del lavoro
Abcuro Appoints Sarah Boyce to its Board of Directors
Fonte
Abcuro, Inc.
Emittente
Business Wire
1.00
0
25/06/2024
Biotecnologia
Sanità
Salute
Medicina - Varie
Oncologia
Abcuro Completes Enrollment of Registrational Phase 2/3 MUSCLE Clinical Trial of Ulviprubart for the Treatment of Inclusion Body Myositis
Fonte
Abcuro, Inc.
Emittente
Business Wire
1.00
0

Recapiti

Social Media

Seguaci
0
Compatibilità
0